伴腺病毒血症的儿童不明原因急性肝衰竭暴发——并非新发疾病
2022年英国报告了免疫正常儿童中与腺病毒血症相关的不明原因急性肝炎及儿童急性肝衰竭(ID-PALF)暴发。本研究纳入伦敦国王学院医院转诊的急性肝炎患儿,比较2022年暴发期与2017-2021年ID-PALF伴腺病毒血症的临床、组织学及结局,发现暴发期病例的肝性脑病、需血管活性药物的低血压及血氨水平更常见,但自体肝生存率相似,结论认为该关联并非新发疾病。
要点
- 2022年1-6月转诊65例急性肝炎患儿,其中10例因ID-PALF入院。
- ID-PALF占2017-2021年全部儿童急性肝衰竭的26%,2022年暴发期为58.8%。
- 暴发期ID-PALF伴腺病毒血症者肝性脑病、需血管活性药物的低血压及血氨更高,自体肝生存率相似。
核心结论
- 伴腺病毒血症的免疫正常儿童ID-PALF并非2022年特有的新发疾病。
- 人腺病毒感染在本次急性肝炎暴发中的唯一病因作用似乎不太可能。
- 作者提供移植患者移植肝的组织学数据不支持直接病毒细胞毒性,该病可能由针对腺病毒和/或腺相关病毒2型的免疫损伤介导。
研究设计与样本
- 研究纳入暴发期间转诊至伦敦国王学院医院(King's College Hospital, London)寻求建议和管理的急性肝炎患儿。
- 从电子健康记录获取2022年ID-PALF频率、移植率及与腺病毒感染关联的数据。
- 比较2017-2021年与2022年ID-PALF伴腺病毒血症患儿的临床表现、组织学及结局。
主要发现
- 2022年1月至6月转诊65例急性肝炎患者,10例儿童因ID-PALF入院。
- ID-PALF占2017-2021年全部儿童急性肝衰竭病例的26%,而2022年暴发期间为58.8%。
- 暴发期间,腺病毒血症存在于52%的无肝衰竭急性肝炎患儿(有腺病毒血症检测结果者)及100%的ID-PALF病例中。
- 2017-2019年全部ID-PALF病例中6/13(46%)免疫正常儿童可见腺病毒血症,2020-2021年6例ID-PALF病例中明确无腺病毒血症。
- 与2017-2019年伴腺病毒血症的ID-PALF(n=6)相比,暴发期间伴腺病毒血症的ID-PALF(n=10)更常出现肝性脑病、需血管活性药物的低血压及更高的血浆氨水平(入院和峰值),自体肝生存率相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In the year 2022, an outbreak of indeterminate acute hepatitis and indeterminate paediatric acute liver failure (ID-PALF) in association with adenoviraemia in immunocompetent children was reported in the UK. We postulate that this association is not a new disease in immunocompetent children. METHODS: Children with acute hepatitis during the outbreak who were referred to King's College Hospital, London for advice and management were included in the study. Data on the frequency of ID-PALF in 2022, as well as transplantation rates and the association with adenovirus infection, were obtained from electronic health records. The clinical presentation, histology and outcomes of children with ID-PALF and adenoviraemia in 2017-2021 were compared with those in 2022. RESULTS: From January to June 2022, 65 patients with acute hepatitis were referred. Ten children were admitted with ID-PALF. ID-PALF constituted 26% of all PALF cases in 2017-2021, in contrast to 58.8% during the 2022 outbreak. During the outbreak, adenoviraemia was present in 52% of children with acute hepatitis without liver failure (in whom adenoviraemia test results were available) and in 100% of ID-PALF cases. Adenoviraemia was seen in immunocompetent children in 6/13 (46%) of all ID-PALF cases between 2017-2019, with a clear absence of adenoviraemia in the 6 ID-PALF cases during 2020-2021. Compared to ID-PALF with adenoviraemia in 2017-2019 (n = 6), ID-PALF with adenoviraemia during the outbreak (n = 10) was associated with more frequent hepatic encephalopathy, hypotension requiring vasoactive medications and higher plasma ammonia levels (admission and peak), with similar native liver survival. CONCLUSIONS: The recent outbreak of ID-PALF with adenoviraemia in immunocompetent children does not appear to be a new disease, contrary to perception and other reports. The frequency of such cases over the years could be linked to background rates of adenovirus infections. IMPACT AND IMPLICATIONS: Indeterminate paediatric acute liver failure (ID-PALF) associated with adenoviraemia in immunocompetent children is not a new disease specific to 2022. The exclusive role of human adenovirus infection in the causation of this outbreak of acute hepatitis seems unlikely. Indeed, we provide histological data from explants in transplanted patients that do not support direct viral cytotoxicity. The disease is probably mediated by immunological injury directed towards adenovirus infection and/or adeno-associated virus-2.
引用
- Jagadisan B, Verma A, Deheragoda M, et al. Outbreak of indeterminate acute liver failure in children with adenoviraemia - Not a new disease. J Hepatol. 2023. PMID: 36822480. doi:10.1016/j.jhep.2023.02.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。